3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms by Site
1
Multiple Chronic Conditions
1
Lung Neoplasms
1
Lung Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
4
Pemetrexed
3
pembrolizumab
2
patritumab
2
osimertinib
2
Sunitinib
2
Standard of Care
2
Paclitaxel
2
Irinotecan
2
Cisplatin
2
Ascorbic Acid
2
valrubicin
1
pralsetinib
1
palbociclib
1
napabucasin
1
linifanib
1
genexol-PM
1
dostarlimab
1
alectinib
1
Watchful Waiting
1
Sorafenib
1
Ramucirumab
1
Patient Reported Outcome Measures
1
Mitomycin
1
KRN-330
1
Interleukin-2
1
Indocyanine Green
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Site
×
Patient Reported Outcome Measures
×
Clear all
NCT03053297
2018-02-08
PANORAMA
AstraZeneca
Terminated
89 enrolled